

Figure 1

2/17

Figure 2 Part I

11fm94400	HKYPEQPGRFAKILLRPAIRSIGLKCLEHLEFFKLIGdtpidflmemleap-----	190 200 210 220 230
BAB13403	-KLAQDAFKIATLMDSLPDTILKVSLELGQWYRMTLstlnwrrremrvrlvtcategvyyaldsimqt	00 410 420 430 440 450 460 4

1 fm 9AA00

BAB13403 wftlfptreatsivattvmsnstivrlhldchqgeklassartlalqcamkdpqncalsaltlcekdhia
70| 480| 490| 500| 510| 520| 530| 5

1 fm 9AA00

BAB13403 fetayqivlidaattgmsytqlftiarymehrgypmrayklaatlamthlnlsynqdtphaindvawacals 6

1 fm 9AA00

BAB13403 hslgknelaai1plvvksvkatvlsdilrrct1ttppmgvlhgrrnsgkmlsldkap1rlglldatigay

1 fm 9AA00

BAB13403 intthsrllthisprhyseefielskaretelfmahdghiqftqfidnlkqiykgkkklmlvrerfg
80| 690| 700| 710| 720| 730| 740|

Figure 2 Part II




Figure 3




Figure 4




Figure 5

7/17




Figure 6

8/17




Figure 7

Dose response LBDG14 agonist # 1




Figure 8




Figure 9




Figure 10

12/17




Figure 11




Figure 12




Figure 13

Fig. 14

Affy ID	Tissue	Disease	Morphology	Mean fluorescent units for control samples	SD for controls	Number of controls	CPC%	Mean fluorescent units for disease samples	SD for disease samples	Number of disease samples	EPC%	Fold Change Disease compared to control	T-Stat
226208_at	Soft tissues, nos	Benign neoplasm of connective and other soft tissues, nos	Schwannoma, nos	446.47	235.79	6	100	1179.7	382.38	7	100	2.64	4.22
226208_at	Lung, nos	Malignant neoplasm of lung, nos	Neuroendocrine carcinoma	527.78	171.91	113	100	293.01	36.84	3	100	-1.8	-8.79
226208_at	Lung, nos	Secondary malignant neoplasm of lung, nos	Squamous cell carcinoma, nos	527.78	171.91	113	100	276.16	38.13	3	100	-1.91	-9.21
226208_at	Stomach, nos	Malignant neoplasm of stomach, nos	Sarcoma, nos	567.17	182.9	53	100	972.59	400.57	8	100	1.72	2.82
226208_at	Small intestine, nos	Malignant neoplasm of small intestine, nos	Sarcoma, nos	453.79	139.29	81	100	1074.08	303.6	4	100	2.37	4.07
226208_at	Small intestine, nos	Malignant lymphoma, nos of unspecified, extranodal or solid organ site	Malignant lymphoma, nos	453.79	139.29	81	100	272.87	117.85	7	85.71	-1.66	-3.84
226208_at	Colon, nos	Secondary malignant neoplasm of colon, nos	Adenocarcinoma, nos	632.74	157.12	188	100	355.15	99.67	3	100	-1.77	-4.68
226208_at	Colon, nos	Malignant lymphoma, nos of unspecified, extranodal or solid organ site	Malignant lymphoma, nos	632.74	157.12	188	100	267.11	60.47	3	100	-2.37	-9.95
226208_at	Kidney, nos	Malignant neoplasm of kidney, nos	Wilms' tumor	3524.18	120.42	94	100	677.87	95.69	8	100	1.9	8.81
226208_at	Kidney, nos	Benign neoplasm of kidney, nos	Oncocytoma	354.18	120.42	94	100	583.81	276.66	10	100	1.65	2.6
226208_at	Testis, nos	Malignant neoplasm of testis, nos	Seminoma, nos	388.96	109.77	8	100	254.38	105.58	8	87.5	-1.53	-2.5
226208_at	Neutrophils	Activated neutrophils (yersinia)		1736.4	1083.98	5	100	3897.07	679.19	7	100	2.24	3.94




Figure 15

Figure 16: Alignment of original sequence prediction (SEQ ID NO: 2) with the extend d sequence prediction (SEQ ID NO: 32)